Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study

Authors :: John M. Vierling
T. Garimella
Robert J. Fontana
Charles S. Landis
Stephanie Noviello
Eugene S. Swenson
Y. Zhao
Timothy Eley
Eugene R. Schiff
Y. Gandhi
Fred Poordad
Source :: Journal of Hepatology. 64:S768-S769
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: medicine.medical_specialty
Daclatasvir
Hepatology
Sofosbuvir
business.industry
Ribavirin
Advanced cirrhosis
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
030211 gastroenterology & hepatology
business
medicine.drug

Tools